Title |
The spectrum of psychosis in multiple sclerosis: a clinical case series
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, February 2017
|
DOI | 10.2147/ndt.s116772 |
Pubmed ID | |
Authors |
Thomas Gilberthorpe, Kara O'Connell, Alison Carolan, Eli Silber, Peter Brex, Naomi Sibtain, Anthony David |
Abstract |
Psychosis in the context of multiple sclerosis (MS) has previously been reported as a rare occurrence. However, recent epidemiological studies have found prevalence rates of psychosis in MS that are two to three times higher than those in the general population. Untreated psychosis in patients with MS can adversely impact on adherence to MS medication, levels of disability, and quality of life. This retrospective case series describes the spectrum of psychotic disorders occurring in association with MS using demographic, clinical, and neuroimaging data. In the discussion, we highlight the particular diagnostic and treatment challenges that such disorders can pose for clinicians and through our case vignettes provide examples of potential interventions for this complex patient population. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 27% |
United Kingdom | 2 | 18% |
Qatar | 1 | 9% |
Unknown | 5 | 45% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 10 | 91% |
Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 94 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 18 | 19% |
Student > Master | 15 | 16% |
Student > Ph. D. Student | 11 | 12% |
Researcher | 9 | 9% |
Student > Postgraduate | 6 | 6% |
Other | 15 | 16% |
Unknown | 21 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 31% |
Psychology | 10 | 11% |
Neuroscience | 9 | 9% |
Nursing and Health Professions | 6 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Other | 9 | 9% |
Unknown | 29 | 31% |